AMCP is your partner in navigating AI’s transformative potential—ensuring patient-centered, ethically sound, and strategically aligned implementation across pharmacy practice and policy.
JMCP Outsert - BTKis in Chronic Lymphocytic Leukemia
Recommendations for treatment initiation in CLL are stratified by disease stage using either the Rai staging system, which defines disease as low-, intermediate-, or high-risk; or the Binet staging system, which defines disease as stage A, B, or C based on the number of lymphoid areas involved and the presence of anemia or thrombocytopenia. Generally, treatment should be initiated in patients with active or progressive disease who are intermediate- or high-risk, or stage B or C.
Related
Retinal diseases in patients with diabetes pose signi cant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.
View our webinar on Managed Care Approaches to Address Unmet Patient Needs in Multiple Sclerosis (MS), a disease affecting nearly 1 million people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
